Exchange: OTC Sector: Healthcare Industry: Biotechnology
0.91% $0.193
America/New_York / 3 mai 2024 @ 15:59
FUNDAMENTALS | |
---|---|
MarketCap: | 80.99 mill |
EPS: | -0.0100 |
P/E: | -19.30 |
Earnings Date: | May 10, 2024 |
SharesOutstanding: | 419.52 mill |
Avg Daily Volume: | 0.331 mill |
RATING 2024-05-03 |
---|
C |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Strong Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -19.30 | sector: PE 29.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.14x |
Company: PE -19.30 | industry: PE 136.10 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.0021 (-101.10%) $-0.195 |
Date: 2024-05-06 |
Expected Trading Range (DAY) |
---|
$ 0.175 - 0.211 ( +/- 9.32%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-29 | Pershing Edward | Buy | 0 | 8% Unsecured Convertible Promissory Note |
2024-04-25 | Pershing Edward | Buy | 37 752 | Series D-1 Convertible Preferred Stock |
2024-04-25 | Pershing Edward | Sell | 0 | 8% Unsecured Convertible Promissory Note |
2024-04-19 | Pershing Edward | Buy | 0 | 8% Unsecured Convertible Promissory Note |
2024-04-11 | Pershing Edward | Buy | 0 | 8% Unsecured Convertible Promissory Note |
INSIDER POWER |
---|
100.00 |
Last 98 transactions |
Buy: 17 761 544 | Sell: 0 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 |
Volume Signals | |
---|---|
Price | $0.193 (0.91% ) |
Volume | 0.129 mill |
Avg. Vol. | 0.331 mill |
% of Avg. Vol | 38.99 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver; uveal melanoma metastatic to the liver; and pediatric solid tumor cancers, such as neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. The company is also developing oral formulations of current good manufacturing practice rose bengal sodium (cGMP RBS) for the treatment of adult solid tumor cancers, such as head and neck, breast, testicular, and colorectal cancers; pediatric blood cancers, including leukemia; coronavirus, an acute respiratory syndrome; multi-drug resistant bacteria, such as gram-negative bacteria; and for eye diseases, including infectious keratitis. In addition, it develops PH-10, an investigational immuno-dermatology agent for the treatment of inflammatory dermatoses, such as psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee.